Double Philadelphia Chromosomes- A Rare, Yet an Important Cytogenetic Phenomenon of Prognostic Significance in De Novo Acute Lymphoblastic Leukemia
Tóm tắt
Presence of additional copies of Philadelphia chromosome (Ph) is characteristic of chronic myeloid leukemia in blast crisis, very rarely observed in de novo acute lymphoblastic leukemia (ALL). Ph positive (Ph+ve) ALL and CML in lymphoid blast crisis (CML-LBC) are biologically different with divergent clinical course. Double Ph+ve ALL has little data available as to its incidence and prognostic significance. We studied five cases of Ph+ve precursor B-cell ALL having an extra copy of Ph chromosome with regard to their clinical and laboratory features. An extensive review of literature was done on prognostic significance and molecular aspects of double Ph in ALL. The study confirms that double Ph was a rare phenomenon in precursor B-cell ALL. It is observed that molecular basis of double Ph positive ALL is less understood compared to CML in blast crisis. The study highlights fundamental role of cytogenetic and molecular studies in diagnosis and management of these patients. Long-term follow-up studies on a larger group of patients are required to understand the prognostic impact of extra Ph in Ph+ve ALL, which is usually resistant to standard chemotherapeutic regimen and often requiring bone marrow transplantation.
Tài liệu tham khảo
Koretzky GA (2007) The legacy of the Philadelphia chromosome. J Clin Invest 17(8):2030–2032
Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES (2011) The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 117(19):5019–5032
Calabretta B, Perrotti D (2004) The biology of CML blast crisis. Blood 103(11):14
O’Dwyer ME, Mauro MJ, Kurilik G, Mori M, Baileisen S, Olson S et al (2002) The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. Blood 100(5):1628–1633
Cao H, Li J, Wu T, Mao D, Wang C, Bai H (2018) Double Philadelphia chromosome-positive B acute lymphoblastic leukemia. Int J Hematol Ther 4(1):34–35
International Standing Committee on Human Cytogenomic Nomenclature. ISCN (2020): an international system for human cytogenomic nomenclature. In: McGowan-Jordan J, Hastings RJ and Moore S, editors. Cytogenet Genome Res. New Delhi: S. Karger Publishers, Inc; 160: 7–8
Secker-Walker LM, Craig JM, Hawkins JM, Hoffbrand AV (1991) Philadelphia positive acute lymphoblastic leukemia in adults: age distribution. BCR breakpoint and prognostic significance Leukemia 5(3):196–199
Tang Y-L, Raja Sabudin RZA, Leong C-F, Ko CC-H, Chia W-K, Salwati S et al (2015) Double Philadelphia chromosome-positive B acute lymphoblastic leukaemia in an elderly patient. Malays J Pathol. 37(3):275–9
de Campos MGV, de ChauffailleLLF M, RodriguesKrumYamamoto CAEAM (2003) A rare case of Acute Lymphocytic Leukemia ALL presenting with double Philadelphia chromosome relapse or secondary leukemia? Genet Mol Biol 26(3):249–51
Takasaki H, Kanamori H, Takabayashi M, Yamaji S, Tomita N, Fujimaki K et al (2003) Double Philadelphia chromosomes-positive acute lymphocytic leukemia. Leuk Lymphoma 44(4):735–736
Wu T, Cao H, Li J, Wu T, Mao D, Wang C et al (2018) Double Philadelphia Chromosome-Positive B Acute Lymphoblastic Leukemia. Int J Hematol Ther. 20(1):34–5
http://cgap.nci.nih.gov/Chromosomes/CytSearchForum
Rieder H, Ludwig W, Gassmann W, Maurer J, Janssen JWG, Gokbuget N et al (1996) Prognostic significance of additional chromosome abnormalities in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia. Br J Hematol 95(4):678–691
Thomas X, Thiebaut A, Olteanu N, Danaila C, Charrin C, Archimbaud E et al (1998) Philadelphia chromosome positive adult acute lymphoblastic leukemia: characteristics, prognostic factors and treatment outcome. Hematol Cell Ther 40(3):119–128
Uckun FM, Nachman JB, Sather HN, Sensel MG, Kraft P, Steinherz PG et al (1998) Clinical significance of Philadelphia chromosome positive pediatric acute lymphoblastic leukemia in the context of contemporary intensive therapies. Cancer 83(9):2030–2039
Shah B, Gajendra S, Gupta R, Sharma A (2015) Novel cytogenetic aberrations in a patient of chronic myeloid leukemia with blast crisis. J Clin Diagn Res. https://doi.org/10.7860/JCDR/2015/12284.5940
Faderl S, Kantarjian HM, Talpaz M, Estrov Z (1998) Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic Leukemia. Blood 91(11):3995–4019
Vinhas R, Lourenco A, Santos S, Ribeiro P, Silva M, de’ Sousa AB et al (2018) A double Philadelphia chromosome-positive chronic myeloid leukemia patient, co-expressing P210BCR-ABL1 and P195BCR-ABL1 isoforms. Haematologica. https://doi.org/10.3324/haematol.2018.192534
Krishna Chandran R, Geetha N, Sakthivel KM, SureshKumar R, JagathnathKrishna KMN, Sreedharan H (2019) Impact of additional chromosomal aberrations on the disease progression of chronic Myelogenous Leukemia. Oncol Front. https://doi.org/10.3389/fonc.2019.00088
Syed NN, Usman M, Adil S, Khurshid M (2008) Additional chromosomal abnormalities in Philadelphia-positive chronic myeloid leukemia. Hematol Oncol Stem Cel Ther 1(3):166–170
Wassmann B, Pfeifer H, Scheuring UJ, Binckebanck A, Gökbuget N, Atta J et al (2004) Early prediction of response in patients with relapsed or refractory Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib. Blood 103(4):1495–1498